York Pharma predicts year of success
Hitchin-based, York Pharma, announced increased pre-tax losses of almost £6m which were in-line with management predictions, but expects a year of commercial success.The period ending September 30 loss was £5.88m compared with £2.69m for the previous year. The firm is confident about the release of its new topical antifungal product, abasol, which is expected to hit the market in early 2007.
It also announced that its new psoriasis drug, Vampex has completed phase IIa clinical trials and eczema treatment Sabarep had entered controlled human trials. The dermatology expert reported a cash pot of £2.9m, generated from the placing of new shares, not included with these results.